Chagas disease and syphilis are considered a mayor public health problem worldwide. Both pathologies affect socio-economic vulnerable population and they are both transmitted congenitally, causing an alarming increasing number of infected newborns. The current diagnostic methods for these diseases are based on serology follow-up until 8 to 10 months from birth, which considering the population usually involved and their scarce resources, usually translates in loosing continuity in their controls and follow-up.
Chagas prevalence in pregnant women is 4% with an incidence of Congenital Chagas disease of 1500 annual cases. From those, only 1 third are diagnosed. In our and other authors experience, the detection of DNA of Trypanosoma cruzi by PCR shows an elevation of parasitemia at birth, with a peak at the first month of life.
Syphilis is a re-emergent pathology, preventable and curable when diagnose is achieved early at the beginning of pregnancy.. The cost-effectiveness of performing screening for this infection is widely demonstrated, preventing high morbi-mortality for children when applied to pregnant women.
For both syphilis and Chagas diagnosis, there are some studies comparing PCR follow-up with conventional serology, but none were validated and there is still need to bring more evidence in order to modify our current practice. We propose a sequential study of PCR for Tryipanosoma cruzi and Treponema pallidum from birth, believing this will increase sensitivity of congenital Chagas and syphilis diagnose and improve follow-up of these patients.
Full Title of Study: “Implementation of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases in Context of ETMIplus Program, OPS/OMS. Multicentric Study”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: July 30, 2021
Clinical Trial Outcome Measures
- Implementation of Bio-molecular Techniques (PCR) for Early Diagnose of Congenital Syphilis and Chagas Diseases
- Time Frame: 2 years
- Evaluate PCR sensitivity, specificity, PPV and NPP in diagnose of congenital syphilis and congenital Chagas diseases and compare it with current methods. We will measure PCR titles during one year in each patient, and then compare results with serologies, in order to assess if PCR positivization and negativization occurs earlier than current methods. This may allow physicians to shorten time required for follow-up in these patients.
- Implementation of Bio-molecular Techniques (PCR) as terapeutic response biomarker for Congenital Syphilis and Chagas Disease
- Time Frame: 2 years
- We will evaluate the utility of PCR as an early biomarker of terapeutic response and compare it to serology for T.pallidum and T. cruzi during and after treatment. This could prevent unnecessary prolonged treatments, and could also allow early diagnose for treatment failures.
- Identification of different genotypes of T.pallidum in samples to create a database of T.pallidum genotypes
- Time Frame: 2 years
- Identification of different genotypes of T.pallidum in samples taken from active skin lessions and blood samples, in order to create a data base of T.pallidum genotypes causing congenital syphilis and acquired syphilis
Participating in This Clinical Trial
- Child under 1 year of age, born from mother positive for syphilis not treated or inadequately treated during pregnancy
- Patients with acquired syphilis
- Child under 1 year of age, born from mother with positive serology test for Chagas
- Patients who had received treatment for syphilis or Chagas previously
- Patients who are not able to complete scheduled visits
- Other diseases that could difficult implementation of this protocol or results interpretation.
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 18 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
- Provider of Information About this Clinical Study
- Principal Investigator: Dr Jaime Altcheh, Principal Investigator – Hospital de Niños R. Gutierrez de Buenos Aires
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.